BioWorld

Tag Archives: ABH

The Good, the Bad and . . . the Huh? A 2011 Biotech Recap

December 28, 2011 – 6:11 pm
Share
By Jennifer Boggs | Posted in Accelerated approval, Antibody, Big pharma, Biologic, Biosimilar, Biotech conferences, Biotechnology, BLA, Cancer, Cardiovascular, China, Clinic, Clinical Trial, Collaboration, Complete Response Letter, Deals, Drug Approval, European Medicines Agency, FDA, Financing, Gene Therapy, Genomics, Healthcare reform, immunotherapy, IND, Investigational New Drug Application, IPO, NDA, New Drug Application, Orphan disease, Patents, PDUFA, Personalized medicine, Pharmaceutical, Phase I, Phase II, Phase III, Pipeline, Preclinical, Rare disease, Reimbursement, RNAi, Uncategorized | Also tagged , , | Comments (1)

Can Other Cell Therapy Firms Avoid Dendreon’s Fate?

December 7, 2011 – 5:43 pm

Stem cell therapies may be relatively early stage, but that hasn’t stopped their developers from giving some serious thought to late stage issues like reimbursement and health economics.

Share
By Trista Morrison | Posted in Reimbursement, Stem cell | Also tagged , , | Comments (0)